Altimmune, a clinical-stage biopharmaceutical company based in Gaithersburg, Maryland, has announced positive topline results from its Phase 2 RECLAIM clinical trial evaluating pemvidutide for the treatment of alcohol use disorder (AUD). The data, released on Tuesday, indicate that the investigational drug, a dual agonist of the glucagon-like peptide-1 (GLP-1) and glucagon receptors, successfully met its primary endpoint by significantly reducing the frequency of heavy drinking days in participants. This development represents a pivotal moment in the evolution of GLP-1 therapies, which have already revolutionized the treatment of type 2 diabetes and obesity, and are now being positioned to address the complex neurological and physiological drivers of addiction.
The preliminary results from the RECLAIM study show that once-weekly subcutaneous injections of pemvidutide led to a statistically significant reduction in alcohol consumption over a 24-week period. Alcohol use disorder remains a massive public health challenge, characterized by an impaired ability to stop or control alcohol use despite adverse social, occupational, or health consequences. According to the National Institute on Alcohol Abuse and Alcoholism (NIAAA), nearly 30 million people in the United States suffer from AUD, yet fewer than 10% receive pharmacological treatment. Altimmune’s entry into this space suggests a burgeoning frontier for metabolic drugs in the realm of behavioral health.
Phase 2 RECLAIM Trial Design and Primary Outcomes
The Phase 2 RECLAIM trial was a randomized, double-blind, placebo-controlled study designed to assess the safety and efficacy of pemvidutide in a specific patient population: individuals suffering from both AUD and obesity. The trial enrolled 100 participants, including both men and women, who reported high baseline levels of alcohol consumption. For the purposes of the study, heavy drinking was defined at baseline as at least 28 drinks per week for men and 21 drinks per week for women.
The primary endpoint of the trial was the change from baseline in the average number of heavy drinking days per week at the end of the 24-week treatment period. A "heavy drinking day" is a standardized metric defined by the NIAAA as five or more drinks in a single day for men and four or more for women. At the 24-week mark, participants receiving pemvidutide showed a reduction in heavy drinking days by an average of 4.2 days per week. In contrast, the placebo group saw a reduction of 2.75 days per week, establishing a statistically significant difference in favor of the study drug.
Beyond the primary endpoint, Altimmune highlighted a critical secondary measure: the percentage of patients achieving total abstinence from heavy drinking. The company reported that 42.2% of participants in the pemvidutide arm reached zero heavy drinking days by the end of the study, a rate more than double that of the placebo group. In the context of regulatory approval, the ability to eliminate heavy drinking days is considered a highly meaningful clinical outcome and a likely requirement for any future registrational studies.
The Dual-Agonist Mechanism: GLP-1 and Glucagon
The scientific rationale behind pemvidutide lies in its unique dual-targeting mechanism. While the current market leaders in the GLP-1 space, such as Novo Nordisk’s semaglutide (Ozempic/Wegovy) and Eli Lilly’s tirzepatide (Mounjaro/Zepbound), focus primarily on GLP-1 or a combination of GLP-1 and GIP (glucose-dependent insulinotropic polypeptide), Altimmune has focused on the synergy between GLP-1 and glucagon.
The GLP-1 component of the peptide is well-known for its role in appetite suppression and weight loss. However, emerging research suggests that GLP-1 receptors in the brain’s reward centers, such as the ventral tegmental area, play a significant role in modulating the "craving and reward" pathways associated with substance use. By activating these receptors, pemvidutide may dampen the dopamine surge typically associated with alcohol consumption, thereby reducing the urge to drink.
The addition of glucagon receptor agonism provides a secondary, organ-specific benefit. Glucagon is known to increase energy expenditure and directly impact liver metabolism. Altimmune, which specializes in liver-directed therapies, noted that glucagon activation helps reduce liver fat, inflammation, and fibrosis (organ scarring). This is particularly relevant for AUD patients, as chronic alcohol consumption is a leading cause of liver cirrhosis and metabolic dysfunction. Christophe Arbet-Engels, Chief Medical Officer of Altimmune, emphasized that this liver-directed impact differentiates pemvidutide from single-receptor GLP-1 drugs, potentially offering a more holistic treatment for the systemic damage caused by chronic alcohol use.
Safety Profile and Tolerability
In the RECLAIM trial, pemvidutide was reported to be generally well-tolerated. The majority of adverse events were classified as mild to moderate in severity, consistent with the known side-effect profile of the GLP-1 class, which typically includes gastrointestinal issues such as nausea and vomiting.
However, one serious adverse event was noted: a case of hyponatremia, or dangerously low sodium levels in the blood. The principal investigator of the trial deemed this event possibly related to the study drug. Hyponatremia can be a concern in populations with high alcohol intake or those undergoing rapid metabolic changes, and Altimmune indicated that more detailed safety data would be forthcoming in peer-reviewed publications and at upcoming medical conferences. Despite this single event, the company maintains that the overall safety profile supports continued clinical development.
Competitive Landscape and Market Analysis
The success of the RECLAIM trial places Altimmune in the middle of a highly competitive "arms race" involving some of the world’s largest pharmaceutical companies. As the obesity market reaches saturation, manufacturers are looking for "GLP-1 plus" indications, with addiction treatment emerging as a primary target.
Currently, Eli Lilly is seen as a major competitor in this niche. Lilly is developing brenipatide, a GLP-1 and GIP agonist, which is already in Phase 3 testing for alcohol use disorder. While Altimmune has reported encouraging Phase 2 data, Lilly’s advanced clinical stage—with a data readout expected in 2028—gives it a significant head start in terms of regulatory timeline.
Analysts from William Blair, Andy Hsieh and Alexandra Ramsey, noted in a research brief that while pemvidutide shows a "robust clinical profile," the road ahead remains challenging. They pointed out that Altimmune will likely require a significant infusion of capital to fund the large-scale pivotal trials necessary for FDA approval. Furthermore, while pemvidutide appears to outperform low-dose semaglutide in early comparisons, the lack of head-to-head trials makes definitive claims of superiority difficult at this stage.
Thomas Smith, an analyst at Leerink Partners, offered a more bullish outlook, suggesting that the RECLAIM results significantly "de-risk" the drug’s clinical and regulatory path. He noted that the specific focus on heavy drinking days as an endpoint aligns well with the FDA’s current thinking on AUD drug development, providing a clear roadmap for the company’s upcoming meetings with the agency.
Strategic Focus on MASH and Future Outlook
While the AUD results are a significant milestone, Altimmune’s primary focus remains Metabolic-Dysfunction Associated Steatohepatitis (MASH), formerly known as NASH. MASH is a severe form of fatty liver disease that can lead to liver failure and cancer. The company is currently preparing to launch a Phase 3 trial for pemvidutide in MASH, following the results of its Phase 2b IMPACT study.
The MASH market is becoming increasingly crowded following the first-ever FDA approval in the space: Madrigal Pharmaceuticals’ Rezdiffra. Other major contenders include Boehringer Ingelheim’s survodutide and Eli Lilly’s triple agonist, retatrutide. Some analysts have expressed caution regarding pemvidutide’s differentiation in the MASH field. William Blair analysts highlighted that without liver biopsy data from the 48-week timepoint of the IMPACT trial, it is difficult to determine if pemvidutide offers a clear advantage over existing therapies.
Nevertheless, the integration of AUD and MASH treatment could be Altimmune’s unique selling proposition. Given that many patients with metabolic disorders also struggle with alcohol consumption, a single drug that addresses weight loss, liver health, and addictive behavior could capture a significant share of the specialized metabolic market.
Chronology of Development
The journey of pemvidutide has been marked by several key milestones leading up to the RECLAIM results:
- 2023: Altimmune reports positive Phase 2 obesity data (MOMENTUM trial), showing significant weight loss and preservation of lean muscle mass.
- Early 2024: The company releases data from the IMPACT trial in MASH, demonstrating a reduction in liver fat.
- July 2024: Topline results from the Phase 2 RECLAIM trial in AUD are announced, meeting the primary endpoint.
- Upcoming (Q3/Q4 2024): Altimmune is scheduled to meet with the FDA to discuss the Phase 3 design for AUD and initiate Phase 3 trials for MASH.
As Altimmune moves toward these regulatory discussions, the broader pharmaceutical industry is watching closely. The potential for a "weight loss drug" to treat the underlying neurobiology of addiction could redefine the treatment of AUD, shifting it from a purely behavioral or psychological intervention to a comprehensive metabolic and neurological therapy.
Altimmune has stated that it will submit the full RECLAIM data set for presentation at a future medical meeting, where the scientific community will look for deeper insights into the drug’s impact on biomarkers of liver health and the long-term sustainability of reduced drinking behaviors. For now, the positive Phase 2 results provide a necessary tailwind for a company navigating a field dominated by giants, offering a specialized alternative in the rapidly expanding GLP-1 landscape.
